CLIA Guidance Draws Industry Criticism On User Comparability Studies

Manufacturers seeking waived status for diagnostic tests should be able to choose a statistically appropriate sample for user comparability tests, according to comments submitted by industry on FDA's March 1 draft guidance on criteria for CLIA waiver applications.